These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12531084)

  • 21. Potential mechanisms causing delayed effects of respiratory syncytial virus infection.
    Openshaw PJ
    Am J Respir Crit Care Med; 2001 Mar; 163(3 Pt 2):S10-3. PubMed ID: 11254545
    [No Abstract]   [Full Text] [Related]  

  • 22. Prevention and treatment of respiratory syncytial virus infections (for advances in pediatric infectious diseases).
    DeVincenzo J
    Adv Pediatr Infect Dis; 1997; 13():1-47. PubMed ID: 9544306
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP; Weisman LE
    Expert Rev Vaccines; 2006 Apr; 5(2):261-8. PubMed ID: 16608425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palivizumab (Synagis) for prevention of RSV infection.
    Med Lett Drugs Ther; 1999 Jan; 41(1043):3-4. PubMed ID: 9924488
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis.
    Speer ME; Fernandes CJ; Boron M; Groothuis JR
    Pediatr Infect Dis J; 2008 Jun; 27(6):559-61. PubMed ID: 18434935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of respiratory syncytial virus: antiviral therapies.
    Jafri HS
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S89-92; discussion S92-3. PubMed ID: 12671458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current respiratory syncytial virus prevention strategies in high-risk infants.
    Weisman LE
    Pediatr Int; 2002 Oct; 44(5):475-80. PubMed ID: 12225544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prenatal prevention of respiratory syncytial virus bronchiolitis.
    Belderbos M; Kimpen JL; Bont L
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):703-6. PubMed ID: 21905778
    [No Abstract]   [Full Text] [Related]  

  • 33. [Illnesses by the human respiratory syncytial virus].
    Stock I
    Med Monatsschr Pharm; 2006 Sep; 29(9):329-34, 335-6. PubMed ID: 16984081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating acute bronchiolitis associated with RSV.
    Steiner RW
    Am Fam Physician; 2004 Jan; 69(2):325-30. PubMed ID: 14765771
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prevention of respiratory syncytial virus bronchiolitis].
    Marchac V
    Arch Pediatr; 2006 Dec; 13 Suppl 5():S12-7. PubMed ID: 17550819
    [No Abstract]   [Full Text] [Related]  

  • 36. Motavizumab for the prevention of respiratory syncytial virus infection in infants.
    Gill MA; Welliver RC
    Expert Opin Biol Ther; 2009 Oct; 9(10):1335-45. PubMed ID: 19764889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulatory constituents of human milk change in response to infant bronchiolitis.
    Bryan DL; Hart PH; Forsyth KD; Gibson RA
    Pediatr Allergy Immunol; 2007 Sep; 18(6):495-502. PubMed ID: 17680907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospects for prevention of bronchiolitis caused by respiratory syncytial virus.
    Chanock RM; Richardson LS; Belshe RB; Kim HW; Parrott RH
    Pediatr Res; 1977 Mar; 11(3 Pt 2):264-7. PubMed ID: 846778
    [No Abstract]   [Full Text] [Related]  

  • 39. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
    Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
    Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases.
    Welliver TP; Reed JL; Welliver RC
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S92-6. PubMed ID: 18820587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.